INBX

NASD Inhibrx Biosciences, Inc.
Oct 8, 2026 · 1:25 AM ET EOD Market Closed

$93.36 ↑ +0.00 (+0.00%) Trading Up from the previous close of $93.36, $3.35 below the day’s high of $96.71

YTD change
+18.18%
vs 20-day SMA
-10.15%
vs 200-day SMA
+2.38%

Price ranges

Previous day
$92.60 $96.96
open $95.52 close $93.41
-$2.11 (-2.21%)
Today
$90.66 $96.71
open $92.02 now $93.36
+$1.34 (+1.46%)
Past week
$92.60 $106.94
from $104.83 now $93.36
-$11.47 (-10.94%)
Past month
$92.60 $128.54
from $114.34 now $93.36
-$20.98 (-18.35%)
This year
$57.30 $155.29
from $79.00 now $93.36
+$14.36 (+18.18%)

Price & Performance

+31.01 (+49.74%) / 6M

$55.99$86.73$117.46$148.20Apr 7Jul 8Oct 7

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 39.9% away from all-time highs of $155.29
  • INBX is up 18% since the beginning of the year
  • INBX is up 179% over the past 12 months
  • INBX is down 18% over the past 1 month
  • 29% of all INBX investors are betting against INBX

INBX reads not so good: price sits above one of the two key moving averages, the 12-month move is +178.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-2.34
Earnings momentum +4.4% Quarterly EPS growth
Quarterly change +4.4%

Valuation

P/E ratio N/A
Enterprise value $1.5B
Beta 3.82

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$133.3M
Debt$181.6K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $1.4B

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Competitor comparison

TickerCompany PriceChange
CSLLY CSL Limited Sponsored ADR $31.51 +1.09%
ARGX argenx SE Sponsored ADR $928.44 -0.22%
ONC BeOne Medicines Ltd. Sponsored ADR $364.02 +0.34%
WXIBF Wuxi Biologics (Cayman) Inc. $7.49 +10.64%
INCY Incyte Corporation $113.44 +0.63%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.